Denali Therapeutics DNLI
NASDAQ DNLI
$20.00 -0.53 (-2.58%)
At close: Oct 2, 2026 · 4:00 PM EDT

Denali Therapeutics (DNLI) Gains from Sales and Divestitures (2017 - 2024)

Updated

Denali Therapeutics' Gains from Sales and Divestitures came in at $14.54 million for FY2024.

Analysis

Denali Therapeutics (DNLI) Gains from Sales and Divestitures (2017 - 2024) Analysis & Trends

Going back to FY2016, Denali Therapeutics' Gains from Sales and Divestitures data covers 4 years.

  • The FY2024 figure represents the lowest annual Gains from Sales and Divestitures since FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Denali Therapeutics 3.20 Bn 3.20 Bn 3.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 14.54 Mn
Jun 30, 2018 -8,000.00
Mar 31, 2018 44,000.00
Sep 30, 2017 -1,000.00
API Access

Denali Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=DNLI&period=max&api_key=YOUR_API_KEY